VIP for CIRS (chronic inflammatory response syndrome, often called mold illness) rests on very limited evidence. The quick answer: the main published study of nasal vasoactive intestinal peptide in CIRS treated 20 patients, had no placebo group, and came from the clinic that developed the protocol.[1] VIP is not FDA-approved for any use, and we found no independent controlled trial. Anyone considering it should know the evidence base is a single uncontrolled series.
This page is part of our longevity peptides hub. For the full picture on this peptide, see the VIP profile.
Bottom line
- Weak evidence: one open-label study of 20 patients supports nasal VIP for CIRS.[1]
- Contested diagnosis: CIRS is promoted mainly by a defined group of clinicians; major allergy and occupational guidelines address mold exposure differently.[2][4][5]
- No approval: VIP is not FDA-approved, and the one large rigorous trial of synthetic VIP, in COVID-19, was negative.[8][9]
- Established alternative: treating specific mold-related diagnoses and fixing the damp building are supported by mainstream reviews.[4]
What CIRS is said to be
CIRS is described by its proponents as an acquired condition of innate immune dysregulation that follows breathing air in water-damaged buildings, producing symptoms across many organ systems at once, such as fatigue, aches, headaches, cognitive problems and light sensitivity.[2] Supporters use a set of tests, including visual contrast sensitivity, hormone and immune markers and, more recently, gene expression panels, to define it and separate it from chronic fatigue syndrome.[3]
CIRS does not appear as a defined disease in major allergy or occupational medicine guidance. A 2016 review by an allergy society workgroup described the health effects of indoor fungi as asthma development and worsening, allergic rhinitis, allergic bronchopulmonary mycoses, allergic fungal sinusitis and hypersensitivity pneumonitis, and called for more research to establish causality for dampness-related effects generally.[4] A 2024 German interdisciplinary guideline likewise sets out a conventional diagnostic approach to indoor mold exposure.[5]
Why VIP was tried
Vasoactive intestinal peptide is a natural 28-amino-acid signaling peptide made by nerves and immune cells. It widens blood vessels, relaxes smooth muscle in airways and gut, and dampens inflammatory signals from immune cells in lab and animal studies.[6] Those immune-calming properties are the rationale for using it in a condition framed as excess innate immune activation.
A practical problem: VIP disappears from blood within about a minute after an intravenous infusion stops.[7] That is why the protocol uses a nasal spray rather than injections, in the hope of reaching tissue locally.
The key study, in detail
| Feature | What the study did |
|---|---|
| Design | Open-label case series, no blinding, no placebo group |
| Size | 20 patients whose illness had not responded to earlier protocol steps |
| Comparison | Historical controls from the same clinic |
| Dose | 50 micrograms nasal VIP four times daily at first, then adjusted |
| Follow-up | 18 months |
| Reported result | Symptoms and several blood markers moved toward normal; no dropouts for side effects; lipase did not rise |
| Authors | The clinic that developed the protocol |
The authors themselves described the results as preliminary and said a placebo-controlled trial had begun.[1] We could not find a published placebo-controlled trial of nasal VIP for CIRS, and searching ClinicalTrials.gov in October 2026 did not turn up a registered CIRS trial of VIP.
What the broader VIP research shows
VIP’s one large, rigorous human test was in a different disease. In TESICO, an NIH-funded trial, 461 hospitalized adults with COVID-19 respiratory failure received intravenous aviptadil (synthetic VIP) or placebo. The trial was stopped for futility; 90-day deaths were 38% with aviptadil and 36% with placebo.[8] That doesn’t test nasal VIP in CIRS, but it shows that VIP’s anti-inflammatory promise in the lab did not carry over to a serious inflammatory illness in people.
Legal and safety status
- FDA status: VIP is not approved in the US for any use. FDA lists it in Category 1 (“under evaluation”) of its 503A compounding list, updated May 14, 2026, which is an interim status rather than an endorsement.[9]
- Side effects: flushing is the most consistent effect of VIP, with faster heart rate and small blood sugar rises reported in volunteers given it intravenously.[7] Long-term nasal use has not been studied in controlled trials.
- Cost and access: it is obtained as a compounded preparation through a prescriber; we don’t name suppliers.
Limitations of this whole area
- No controlled trial of nasal VIP for CIRS has been published.
- CIRS biomarker work comes largely from the same research group and has not been independently validated.[3]
- Symptoms attributed to CIRS overlap with many conditions, including thyroid disease, sleep apnea, anemia, depression and chronic fatigue syndrome, so a confident diagnosis matters.
What’s reasonable to do instead
Mainstream reviews support identifying and treating the specific condition and reducing exposure: repairing leaks and controlling moisture, treating asthma, allergic rhinitis or sinusitis on their merits, and evaluating alternative explanations for multi-system symptoms.[4][5]
Other peptides are also promoted for immune support with limited evidence. For comparison, see thymosin alpha-1 vs LL-37, our Khavinson peptide bioregulators guide, and the thymosin alpha-1 profile. For how to judge this kind of study yourself, our peptide clinic vs DIY guide covers the safety and legal side.
Questions to discuss with a clinician
- What else could explain my symptoms, and which tests would rule those out?
- What is the evidence behind each step of a proposed protocol?
- What is my building’s moisture situation, and who can assess it?
- If I try a compounded peptide, how will we judge whether it is helping, and when would we stop?
